ADOCIA Announces Half-Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets
Under the liquidity agreement entrusted by
- Number of shares: 43,323
- Cash balance of the liquidity account: € 67,285.71
During the 1st half of 2025, a total of:
Buy-side |
241,009 shares |
€ 1,085,185.84 |
1,291 transactions |
Sell-side |
229,202 shares |
€ 1,055,591.30 |
1,252 transactions |
The following resources appeared on the last half year statement on
- Number of shares: 31,516
- Cash balance of the liquidity account: € 96,275.08
The following resources appeared on the liquidity account when the activity started:
- Number of shares: 15,026
- Cash balance of the liquidity account: € 300,000.00
The liquidity agreement complies with AMF Decision n° 2021-01 of
About
The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® technology for the development of new generation insulins and products combining different hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel®, a long-acting drug delivery platform.
Disclaimer
This press release contains certain forward-looking statements concerning
The forward-looking statements contained in this press release are also subject to risks not yet known to
View source version on businesswire.com: https://www.businesswire.com/news/home/20250716229749/en/
CEO
contactinvestisseurs@adocia.com
Tel : +33 4 72 610 610
www.adocia.com
Ulysse Communication
Adocia Media and Investor Relations
adocia@ulysse-communication.com
+ 33 (0)6 87 88 47 26
Source: